Product Name:
Src-pY530
Product Number:
ab-pk948
Target Full Name: Src proto-oncogene-encoded protein-tyrosine kinase
Target Alias: ASV; c-Src; p60-SRC; p60-Src; SRC1; ASV; CCDS13294.1; ENSG00000197122
Product Type Specific: Src protein kinase phosphosite-specific antibody
Antibody Code: PK948
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y530
Protein UniProt: P12931
Protein SigNET: Src
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human Src
Antibody Immunogen Sequence: EPQ(pY)QPG(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues E327 to G333. Src Y530 phosphorylation inhibits phosphotransferase activity and induces interaction with Src and AFAP. This is a major site of in vivo phosphorylation of Src (≥989 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). Src is known to be phosphorylated at this site in vitro by Chk1 (CHEK1), CSK, CTK (MATK), and Src.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish.
Related Product 1: SrcSubtide kinase substrate peptide (Cat. No.: PE-01BJK95)
Related Product 2: CDK1 (6-20) KinSub kinase substrate peptide (Cat. No.: PE-01ADT95)
Related Product 3: Src Y419 phosphorylation antibody (Cat. No.: AB-PK818)
Scientific Background: Src is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor protein-tyrosine kinase that is widely distributed from low to moderate levels in most human tissues with highest expression in pancreas and stomach. Src was originally identified as a transforming protein of the Rous sarcoma virus (RSV) that had enzymatic ability to phosphorylate tyrosine in protein substrates. Src is activated by phosphorylation at S12, S75, Y419 and T420. S12 phosphorylation promotes interaction with PPP2R2C and Y410 phosphorylation induces interaction with Cbl-c. Phosphorylation at S17 may reduce phosphorylation at S12. Phosphorylation of S97 and Y530 inhibits Src phosphotransferase activity. Src is overexpressed and activated in a large number of human malignancies and has been linked to the development of cancer and progression to distant metastases. In addition to increasing cell proliferation, a key role of Src in cancer seems to be the ability to promote invasion and motility, functions that might contribute to tumour progression. Src has also been linked with the development of colon cancer. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis. Although mutations that increase the catalytic activity of Src are well known, such as loss of the inhibitory tyrosine phosphorylation site at the C-terminus of the kinase, it is not subject to higher rates of mutations in human tumours than most proteins. Inhibition of Src/c-Abl rescued the degeneration of iPSC-derived motor neurons from patients with familial ALS mutations in SOD1, C9orf72, TARDBP, and from sporadic ALS patients (1). This description may include information annotated by UniProt and/or Google AI.